The liver in sepsis

Severe sepsis and septic shock remain a thorny issue in public health care because of their high mortality rate, which has been reported to be between 30% and 50% [1,2]. Sepsis can evolve to multiple organ dysfunction syndrome (MODS), whose severity accounts for a high mortality rate. During sepsis, liver dysfunction is one of th e MODS components and usually is associated with a poor prognosis but its precise incidence remains unclear. Whereas the liver plays a pivotal role in regulating a wide range of key metabolic, homeostatic, and host-defense activities, liver dysfunction is commonly viewed only as a consequence of shock and initial tissue hypoperfusion. In fact, the injured liver may be considered one of the main actors in the genesis and amplifi cation of multiple organ failure. However, the lack of reliable diagnostic tools does not allow detection of early liver dysfunction [3]. Th is concise overview aims to describe the epidemiology and prognostic value of liver dysfunction during sepsis, then to review the pathophysiological aspects and clinical features of liver dysfunction, and fi nally to propose a main therapeutic axis and perspectives on specifi c treatment.


Introduction
Severe sepsis and septic shock remain a thorny issue in public health care because of their high mortality rate, which has been reported to be between 30% and 50% [1,2]. Sepsis can evolve to multiple organ dysfunction syndrome (MODS), whose severity accounts for a high mortality rate. During sepsis, liver dysfunction is one of th e MODS components and usually is associated with a poor prognosis but its precise incidence remains unclear. Whereas the liver plays a pivotal role in regulating a wide range of key metabolic, homeostatic, and host-defense activities, liver dysfunction is commonly viewed only as a consequence of shock and initial tissue hypoperfusion. In fact, the injured liver may be considered one of the main actors in the genesis and amplifi cation of multiple organ failure. However, the lack of reliable diagnostic tools does not allow detection of early liver dysfunction [3]. Th is concise overview aims to describe the epidemiology and prognostic value of liver dysfunction during sepsis, then to review the pathophysiological aspects and clinical features of liver dysfunction, and fi nally to propose a main therapeutic axis and perspectives on specifi c treatment.

Septic liver dysfunction: incidence and defi nitions and impact on mortality
Th e precise incidence of sepsis liver dysfunction remains diffi cult to establish because of the lack of a precise and consensus defi nition and the various observation times. Sands and colleagues [4] defi ned liver failure as a combination of a total bilirubin level of greater than 2 mg/dL (>34 μmol/L) and either an alkaline phosphatase or serum aminotransferase level of greater than twice the normal value. In a cohort of 1,342 episodes of sepsis syndrome, liver failu re was present in 12% within 28 days of the onset of disease [4]. Conversely, using the Inter national Classifi cation of Diseases, Ninth Revision, Clinical Modi fication (ICD-9-CM) codes, Angus and colleagues [5] identifi ed 192,980 cases of severe sepsis in seven states in the US and observed hepatic failure in only 1.3%. However, this small incidence is explained by a strongly restrictive defi nition of liver dysfunction, including only acute and subacute necrosis of the liver and hepatic infarction. In a more recent clinical trial involving 312 patients in septic shock, acute liver failure was reported in 20% during the 72-hour period of the study treatment [6]. Th is acute liver failure was defi ned by at least two of the following items: (a) bilirubin of greater than 2.5 mg/ dL (>43 μmol/L), (b) serum alanine transaminase concentration of more than twice the upper limit, and (c) prothrombin time of greater than 1.5 times the control value or an inter national normalized ratio of greater than 1.5 [6]. Th e 2001 International Sepsis Defi nitions Conference recom mended the use of scoring systems, such as the Sepsis-related Organ Failure Assessment (SOFA) score, the MODS score, or the Logistic Organ Dysfunction System (LODS) score [7]. All of these scores aim to quantify the degree of organ(s) dysfunction(s) over the course of sepsis and use bilirubin to assess and defi ne liver dysfunction in addition to prothrombin time for the LODS score. In this conference, sepsis liver dysfu nction was defi ned as a plasma total bilirubin of greater than 4 mg/dL (>70 μmol/L) [7], but, interestingly, this cutoff value was not proposed by any of the cited scoring systems. Except for the early phase of severe sepsis/septic shock in which an acute elevation of serum amino transferase levels (20-fold the upper limit of normal) permits the diagnosis of hypoxic hepatitis (HH) [8], serum bilirubin could be assumed to be the most widely used and proposed biomarker to diagnose hepatic dysfunction/failure during sepsis. Th us, using the SOFA score, the French EPISEPSIS (EPIdemiology of SEPSIS) study group reported incidences of liver dysfunction (hepatic score of greater than 0) and liver failure (hepatic score of 3 or 4) of 46.6% and 6.3%, respectively, in 541 patients with severe sepsis during the fi rst 24 hours after admission to the intensive care unit (ICU) [9]. In the same population and with the same score, the PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) trial reported incidences of liver dysfunction (hepatic score of 1 or 2) and liver failure (hepatic score of 3 or 4) of 35.6% and 2.75%, respectivel y [10].
Developing the MODS sc ore, Marshall and colleagues [11] evaluated the association of multiple hepatic biomarkers -bilirubin, albumin, alkaline phosphatase, aspar tate and alanine aminotransferases (ASAT and ALAT, respectively), and lactate dehydrogenase (LDH)with ICU mortality rate in 692 patients to fi nd the ideal descriptor of liver dysfunction. Unfortunately, neither a single biomarker nor a combination of variables could predict a mortality rate of greater than 50% at the highest increment of abnormality. Nevertheless, the authors selected bilirubin as the hepatic component of their score, arguing that bilirubin satisfi ed most of the criteria for the ideal descriptor of liver dysfunction; that is, bilirubin has a simple, routine, and reproducible dosage; is a comprehensive refl ection of physiological liver function; and is readily evaluable in heterogeneous groups of critically ill patients [11]. However, the authors mentioned the failings of this criterion (that is, its lack of specifi city and its inability to refl ect the full spectrum of liver dysfunction and diff erentiate an acute response from a pre-existing organ chronic disease) [11].
Some authors have argued for the use of a dynamic test, such as the plasma indocyanine green (ICG) disappearance rate (PDR ICG ), to assess liver function [12]. ICG is an organic anion that is exc lusiv ely eliminated by the liver and could estimate hepatic cell function and blood fl ow. Th is technique may detect septic liver dysfunction earlier than bilirubin and seems to correlate with patient outcome but is unable to distinguish the relative contribution of hepatic blood fl ow alterations to hepatocellular injury [13,14]. Moreover, an animal study questioned PDR ICG as a marker of liver cell function. In hyperdynamic porcine endotoxemia, PDR ICG failed to refl ect liver dysfunction as neither hepatic blood fl ow nor PDR ICG exhibited any changes over time, whereas the cumulative bile fl ow, biliary ICG, and bicarbonate excretion fell dramatically [15].
Finally, assessing liver function among critically ill patients remai ns challenging, and neither static nor dynamic tests can be consider ed a gold standard. Th is issue could contribute to an underestimation of the frequency and importance of sepsis liver dysfunction during the course of sepsis. Because liver dysfunction is strongly associated with mortality in patients with sepsis, the ability to accurately assess liver function is of critical interest. Th e EPISEPSIS study group found that the persistence or development of liver failure in the 72-hour period after the onset of severe sepsis was strongly associated with outcome [9]. Furthermore, in the PROWESS trial, the lack of baseline liver dysfunction resolution or the development of new liver dysfunction during the fi rst week of sepsis or both were associated with a lower 28-day survival rate [10]. Similarly, Hebert and colleagues [16] found a signifi cant increased risk of death associated with hepatic failure in patients with sepsis. In the US, mortality was higher in patients meeting the criteria of severe sepsis with hepatic dysfunction based on the ICD-9-CM [5]. Finally, with respect to HH, the presence of septic shock is an independent predictor of overall mortality [8]. Despite this important clinical issue, rec ent important trials on severe sepsis neglected to report specifi c data about liver function [17,18]. Th ese data demonstrate the critical importance of the too-oftenneglected liver dysfunction in the outcome of severe sepsis and septic shock and the urgent need to improve the diagnosis and management of liver dysfunction.

Pathophysiological aspects
Th e pathophysiological aspects of liver dysfunction are complex and not yet wel l understood. Basically, the liver has a role in endotoxin and bacteria scavenging, detoxi fication, and synthesizing proteins for metabolic, immune, and coagulation functions. Several cells are involved in these processes: hepatocytes (HCs), Küpff er cells (KCs), and sinusoidal endothelial cells (SECs). To ensure these functions, liver perfusion, which represents 25% of the cardiac output, is accomplished mainly by portal venous blood fl ow. Th is fl ow is regulated by the hepatic arterial buff er response, which aims to compensate any reduction i n portal blood fl ow [19].
During the course of septic shock, the liver contributes actively to host defense and tissue repair through crosstalk between hepatic cells and blood cells. HCs will shift their metabolic pathway toward upregulation of the infl ammatory response, which is responsible for an increase in the synthesis of acute-phase proteins mediated predominantly by interleukin 6 (IL-6) [20]. Th is shift leads to increases in C-re active protein, α-1-antitrypsin, fi brinogen, prothrombi n, and haptoglobin levels, whereas the hepatic production of albumin, transferring, and antithrombin is decreased. In addition, the upregulation of the acute-phase response inhibits the pr otein C pathway, and the profound changes in the balance of coagulation factors result in pro-coagulant activity in sepsis. Moreover, glucose metabolism is signifi cantly altered because of increases in glycogenolysis and gluconeogenesis [21], and liver hypermetabolism, such as increased amino-acid uptake, occurs [22]. In addition, the metabolic changes and infl ammatory response lead to a decrease in biotransformation liver function, especially a reduction in cytochrome P450 activity. Th us, the elimination of endobiotic and xenobiotic compounds is considerably impaired [23,24]. In contrast, KCs are key cells involved in scavenging bacteria and endotoxin. Th e liver harbors approximately 80% of al l macrophages in the human body as resident KCs [25]. Indeed, endotoxin clearance was impaired in the case of underlying liver disease, which could explain a higher susceptibility of the host to infection [26]. KCs can produce various pro-infl ammatory mediators, including tumor necrosis factor-alpha (TNF-α), known to be largely involved in systemic infl ammatory response syndrome (SIRS), the enhancement of hepatic acute-phase proteins, and the production of nitric oxide (NO) [27]. KCs also interact with blood cell com ponents (platelets, erythrocytes, and leukocytes), promoting neutrophil recruitment in the sinusoids and enhancing the pro-infl ammatory response [3]. Hepatic injury can worsen through the adhesion of neutrophils to SECs, promoting thrombi formation in the sinusoids and impairing liver microvascular perfusion [ 3].

Cellular and molecular eff ects
Except for HH, several experimental data argue for an early and insidious liver dysfunction during the initial phase of sepsis. To date, however, this early liver dys function has not been easily detectable in clinical practice.
Exogenous mediators, notably lipopolysaccharide (LPS), have direct and indi rect cytotoxic eff ects on HCs and trigger HC metabolic changes [28][29][30]. Moreover, several cytokines that can induce hepatocellular dysfunction are produced by KCs in response to endotoxin (Table 1) [31]. Am ong them, TNF-α is considered to be the cornerstone cytokine of SIRS develop ment and can directly stimulate HCs to induce IL-6 production. IL-6 is considered the main cytokine implicated in the liver infl ammatory response and is also produced by SECs [32], KCs, and HCs after LPS stimulation [29]. In combination with IL-1β and TNF-α, IL-6 is widely involved in the stimulation of acute-phase protein production [3]. IL-6 can also induce the activation and release of transforming growth factor-beta, which cou nteracts the extension of the infl amma tory response and thus alters the response toward potential immunosuppression [33]. Notably, recent experi mental data suggest that hepcidin most predominantly secreted by the HCs can modulate acute infl amm atory response by the suppression of IL-6 and TNF-α [34]. As cholestatic liver in jury is associated with a downr egulation of hepcidin levels, hepcidin pretreatment signi fi cantly reduced HC pro-infl ammatory cyto kines, leading to reduced early lethality in mice receiving LPS [35].
Another major cytokine responsible for the hepatocellular dysfunction is IL-18. Th is cytokine, secreted by KCs after LPS treatment, plays a critical role in LPSinduced liver toxicity. Th us, LPS can induce the production of a pro-IL-18 cytokine that needs to be cleaved into a biologically active form by caspase-1-dependent process ing. After maturation, IL-18 causes the secretion by hepatic lymphocytes of interferon-gamma (IFN-γ), which is itself responsible for direct liver injury via HC apoptosis, and a second elevation of TNF-α [36]. Interestingly, IFN-γ is al so able to upregulate the expression of the Toll-like receptor 4 [37], which participates in an infl ammatory hyper-reactive response to LPS, leading to a potentially h armful, whole-body infl ammation response. Like cytokines, reactive oxygen species participate in the liver response to LPS. Despite controversies, during the early stage of sepsis, NO is thought to be responsible for the decreased vascular resistance to maintain adequate tissue perfusion, and during the later course of sepsis, excessive NO release is responsible for generalized hypotension. Th e benefi cial eff ects of NO seem to lie in the subtle control of its production by inducible NO synthase and constitutively expressed NO synthase by KCs, HCs, and SECs [38]. Th e functions of NO include the maintenance of vascular integrity and hepato splan chnic blood fl ow, relaxation of vascular smooth muscles, and inhibition of leukocyte adherence to endothelial cells and platelet aggregation. Low NO levels could be hepatoprotective in sepsis [39]. In response to the vasodilator eff ect of NO, circulating endothelin-1, a strong vaso constrictor that is involved in the dramatic reduction of blood fl ow in liver sinusoids, is increased. By stimulating the shift of perisinusoidal Ito cells (also called stellate cell s) from their storage pheno type toward their activated contractile state, endothelin-1 reduces the diameters of hepatic sinusoid vessels [40].
Lipid mediators, such as platelet-activating factor and arachidonic acid metabolites of cyclooxygenase or lipoxygenase, can also promote direct liver injury by an imbalance in their production [30,41]. For example, thromboxane A2 may contribute to platelet aggregation and vasoconstriction, but its contribution is probably less than that of endothelin-1, which can more potently reduce blood fl ow through the hepat ic si nusoids [42].
Interestingly, an increase in gut-released norepinephrine during the early stage of sepsis has recently been shown to be involved in hepatocellular dysfunction. Th e activation of the α2-adrenergic pathway in KCs by this catecholamine leads to the secretion of TNF-α, IL-1β, and IL-10 [43,44].

Clinical events
At the bedside, liver dysfunction is non-univocal, and two schematic clinical features may be observed: HH mainly as a result of a n extrahepatic vascular event and jaundice or sepsis-induced cholestasis as the consequence of an insidious and slow intrahepatic injury. Despite sharing some similarities, these features are quite diff erent.

Hypoxic hepatitis
HH is defi ned according to three criteria [8,45]: (a) a clinical setting of cardiac, circulatory, o r respiratory failure; (b) a dramatic and transient increase in serum aminotransferase activity (at least 20-fold higher than the upper limit of normal); and (c) the exclusion of other putative causes of liver cell necrosis. Septic shock with HH represents up to 32% of all HH cases in ICU patients [8] and can lead to fulminant hepatic failure. In cardiogenic shock, HH is secondary to decreased cardiac output and oxygen delivery. However, in septic shock, splanchnic blood fl ow and cardiac output are increased but not suffi cient to counterbalance the high demands for oxygen and the inability of liver cells to extract oxygen [46]. Moreover, vascular mechanisms of defense against portal blood fl ow reduction are altered, especial ly the hepatic arterial buff er response [19]. Compromised liver hemodynamics, however, do not always lead to HH. Endotoxins and pro-infl ammatory mediators could have an important role in potentiating HH development. Although the mechanisms are not fully understood, HH could result from the reoxygenation phase caused by the ischemia/reperfusion phenomenon, including oxidant stress, early activation of KCs, and secondary recruitment and activation of systemic neutrophils [47]. Th e enzymatic pattern of HH starts with sharp but unsustained increases in ASAT, ALAT, and LDH levels 24 hours after the initiation of shock; decreasing levels are observed 2 or 3 da ys later, and normal levels are reached in approximately 15 days. Th e other hallmark of HH is an early and dramatic drop in prothrombin levels [47], which is respon sible for hemorrhagic syndrome. A serum creatinine level of greater than 20 mg/L (>177 μmol/L) was observed in 65% of HH but probably refl ects the renal impairment caused by the hemodynamic failure [8,48]. In addition, a delayed elevation of bilirubin in HH is described but, in most cases, without visible jaundice.

Jaundice or sepsis-induced cholestasis
Clinical jaundice is usually associated with severe infections such as pneumonia, Gram-negative bacterial sepsis, or septic shock [49,50]. An observational study conducted in 283 critically ill patients revealed sepsis as one of the most important promoters of hyperbilirubinemia (>2 mg/dL or 34 μmol/L) [5 1]. Commonly during sepsis, increased bilirubin levels are a late event in the course of multiorgan dysfunction [52]. In a large cohort of ICU patients, 11% had an 'early' hepatic dysfunction defi ned as a bilirubin concentration of greater than 2 mg/ dL (>34 μmol/L) within 48 hours of admission [51]. Liver histol ogical studies in patients with bac teremic jaundiced showed a predomin ant intrahepatic cholestasis [53]. Among their various functions, bile and bile acids are involved mainly in gut trophicity and gut barrier integrity [54]. Th eir transport and excretion into th e canalicular duct are highl y dependent o n energy and oxygen. HCs are dual-polarity cells that have both basolateral and canalicular membranes. Bile formation is an active osmotic process that involves the crossing of organic and inorganic molecules through the canalicular membrane followed by passive movement of water. Bile formation also requires the correct functioning of integral membrane pro teins (that is, an intact cytoskeleton, tight junctions, and intracellular signal transduction) [55]. First, unconjugated bilirubin uptake is promoted at the basolateral membrane and conjugated bilirubin transported across the canalicular membrane by an Table 1

Cytokines Eff ects of cytokines References
TNF-α Pro-infl ammatory response and stimulation of IL-6 production by HCs [31] IL-6 Pro-infl ammatory response, stimulation of acute-phase proteins, and activation and release of TGF-β [29,[31][32][33] IL-1β Pro-infl ammatory resp onse and synergistic action with TNF-α [3,31 ] TGF-β Anti-infl ammatory response and counteracting of the extension of infl amma tory response [33] IL-18 LPS-induced liver toxicity and secretion of IFN-γ [36] IFN-γ HC apoptosis, elevation o f TNF-α, and upregulation of CD14 [30] IL-10 Anti-infl ammatory response and downregulation of LPS-induced IL-6 release [32] HC, hepatocyte; IFN-γ, interfe ron-gamma; IL, interleukin; LPS, lipopolysaccharide; TGF-β, transforming growth factor-beta; TNF-α, tumor necrosis factor-alpha. energy-dependent multidrug-resistant protein 2 (MRP2) pump [56] (Figure 1a). Basolateral membranes facilitate bile acid transport into HCs: unconjugated bile acids are taken up by members of the s olute carrier organic anion transporter family (SLC21), formerly known as organic anion-trans porting polypeptides (OATPs), and conjugated bile acids are transported into HCs mainly by the sodium taurocholate cotransporting polypeptide (NTCP), which is helped by an AT P-dependent Na/K/ ATPase pump. Effl ux systems for bile acids also exist at basolateral poles. At the canalicular membrane, bile acids are excreted mainly by an ATP-dependent bile salt export pump (BSEP) [57]. Furthermore, a bile acid-independent bile fl ow (BAIBF) participates in bile fl ow generation and involves the active secretion of inorganic electrolytes, such as bicarbonate. During sepsis, most of these steps can be impaired b ecause of a lack of energy such as hypoxia or hypoperfusion or both [56], and BSEP is a major bile fl ow-limiting factor at the canalicular level ( Figure 1b). Endotoxins or pro-infl ammatory cytokines cause direct impairment of bile fl ow through alterations of both transcriptional and post-transcriptional gene expression of bile acid transporters, resulting in the down regulation of transporter proteins [53]. Cytokines promote oxidant stress that results in the inhibition of cAMP-dependent transport function [58] and BAIBF. Finally, endotoxins severely alter the cyto skeletal architecture of HCs contributing to the distur bance of bile fl ow (Figure 1b) [55]. All of these alterations contribute to hyperbilir ubinemia associated with an intrahepatic cholestasis, the severity of which likely depends on the intensity of the impaired steps in bile formation. Th e reduction of bile fl ow or the absence of intraluminal bile can lead to intestinal mucosal atrophy [54] and then deprives the gut of its bacteriostatic neutralizing eff ects and promotes an increase of endotoxin blood levels [59,60]. Th is endotoxin release participates in direct bile fl ow reduction and thus might enter the liver in a vicious circle promoting MODS.

Therapeutic considerations
No specifi c therapeutics for liver sepsis dysfunction/ failure are currently available. Nevertheless, a set of recommendations could be given from the perspective of liver dysfunction/failure. Th us, sepsis liver management relies fi rst on early goal-directed resuscitation as recommended (that is, early antibiotic therapy and infection source control, fl uid resuscitation, and vasopressor support to restore perfusion in the liver and other organs as well as support for the associated organ failure) [61]. Indeed, an appropriate hemodynamic restoration permits the restoration of liver perfusion and is an essential step in avoiding liver dysfunction. Interestingly, experimental data suggest that catecholamines could have an eff ect in the infl ammatory response and participate in hepatic dysfunction [29]. Corticosteroid use in septic shock is still debated, but with respect to the liver, experimental data suggest that they may have an immunomodulation eff ect on sepsis-induced cholestasis through the induction of hepatobiliary transporters and restoration of bile transport [62]. Moreover, in the CORTICUS (Corticosteroid Th erapy of Septic Shock) study, hydrocortisonetreated patients demonstrated a faster improvement in liver failure (SOFA hepatic score of 3 or 4) during the fi rst week (P <0.0001) [63]. However, at present, the use of corticosteroids cannot be recom me nded for the treatment of sepsis-induced hepatic dysfunction.
For hemodynamically stable patients with a functioning gastrointestinal tract, early enteral feeding has become a recommended standard of care [64]. Th erefore, because of the potential favorable eff ects on the gut barrier and oxygenation, enteral nutrition (EN) should be preferred in patients with jaundice [65,66]. EN has also been associated w it h decreased infection rates and fewer metabolic complications in liver disease and after liver transplant compared with parenteral nutrition [67]. Furthermore, EN stimulates bile acid secretion and promotes the resurgence of the enterohepatic cycle [68]. Because hypoglycemia is a frequent event in liver failure, the close monito ring of glycemic levels and careful glucose adminis tration are required and aggressive insulin therapy should then be used with caution [69].
Drugs potentially inducing cholestasis or hepatocellular damage -for example, acetaminophen, non-steroid antiinfl ammatory drugs, benzodiazepines, phenytoin, sodium valproate, amiodarone, antifungals, rifampicin, isonia zid, and fusidic acid -should be avoided or at least used with caution [70]. Moreover, recent genomic studies suggest that polymorphisms in genes involved in molecule metabolism could be an interesting way to defi ne groups of patients at risk of drug-induced liver toxicity [71]. Because ursodeoxycholic acid, a chelator of bile acids, has cytoprotective and immunomodulatory eff ects, it has been used to treat cholestatic di seases (for example, primary biliary cirrhosis). Th ese molecules could be considered for sepsis-induced cholestasis [72], but no data currently support such an assertion. Finally, extracorporeal liver devices have been propo sed to remove endotoxins, such as by hemoperfusion with a polymixin B membrane, or to remove albumin-bound toxins, such as by the molecular adsorbents recirculating system (MARS®; Gambro Hospal, Peterborough, UK). Th eir eff ectiveness and safety have yet to be demonstrated.

Conclusions
Sepsis-induced liver dysfunction is a frequent event and is strongly associated with mortality. During the past few decades, its pathophysiology, including hypoxic and choles tasis aspects, has been better understood. However, the tools to diagnose liver dysfunction earlier and more accurately remain limited. At this t ime, the treatment of liver dysfunction is included only in the general therapeutic steps on sepsis syndrome management. An earlier and better identifi cation of patients with liver dysfunction is warranted and may be the way to evaluate new therapeutic strategies and further improve the prognosis of sepsis.  (1) downregulation of sodium taurocholate cotransporting polypeptide (NTCP); (2,3) reduction of the canalicular export pumps, bile salt export pump (BSEP) and multidrug resistant-associated protein 2 (MRP2); (4) disruption of the structural and functional integrity of the tight junctions; and (5) cytoskeleton alteration surrounding the canaliculus, inducing its distension and a decrease in canalicular duct contractibility. Alb, albumin; CB, conjugated bilirubin; CYP, cytochrome P450; ER, endoplasmic reticulum; GST, glutathione transferase; LP, lipoprotein; OATP, organic anion-transporting polypeptide; UB, unconjugated bilirubin; UDP-GT, uridine diphosphate glucuronosyltransferase. response syndrome; SOFA, sepsis-related organ failure assessment; TNF-α, tumor necrosis factor-alpha.